8-K 1 eightk.txt EIGHTK.TXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 23, 2003 ---------------------------------------------------------------- Generex Biotechnology Corporation ------------------------------------------------------ (Exact name of registrant as specified in its charter) Delaware 000-25169 82-049021 ---------------------------- --------------- -------------------- (State or other jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification No.) 33 Harbor Square, Suite 202, Toronto, Ontario Canada M5J 2G2 ------------------------------------------------------------ (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code 416/364-2551 --------------------------------------------------------------- ------------------------------------------------------------- (Former name or former address, if changed since last report) Item 5. Other Events On May 23, 2003, Generex Biotechnology Corporation issued a press release announcing that Generex and Eli Lilly and Company have agreed to end their development and license agreement for the development and commercialization of buccal delivery of insulin. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. (c) Exhibits Exhibit No. Description ----------- ----------- 99.1 Press release dated May 23, 2003. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENEREX BIOTECHNOLOGY CORPORATION Dated: May 27, 2003 By: /s/ Rose C. Perri -------------------------- Rose C. Perri Chief Operating Officer (principal financial officer) Exhibit Index ------------- Exhibit No. Description ----------- ----------- 99.1 Press release dated May 23, 2003